头颈癌原发放化疗中残余肿瘤乏氧:重复FMISO-PET前瞻性试验最终结果
该前瞻性研究在25例探索队列基础上,另纳入25例头颈鳞癌患者,于放化疗前及期间四个时间点行FMISO-PET/CT,验证残余乏氧对局部区域控制的影响。多个FMISO-PET参数验证成功,治疗第1–2周后预测性能最高(ci=0.77–0.81),第2周残余乏氧体积截断值可验证并区分局部区域控制显著不同的风险组。
要点
- 放化疗期间的残余肿瘤乏氧,而非治疗前乏氧,是乏氧介导治疗抵抗的主要驱动因素。
- FMISO-PET参数在治疗第1–2周后预测局部区域控制性能最高,ci为0.77–0.81。
- 第2周残余乏氧体积截断值可验证,并可将患者分为局部区域控制显著不同的组。
核心结论
- 研究验证了头颈鳞癌放化疗期间的残余肿瘤乏氧是治疗抵抗的主要驱动因素。
- 治疗第2周后FMISO-PET测量的乏氧可作为生物标志物,用于筛选标准放化疗后局部区域复发高危患者。
研究设计与样本
- 前瞻性验证队列研究,在探索队列25例头颈鳞癌患者基础上,另纳入25例患者。
- 于放化疗前及期间四个时间点采集FMISO-PET/CT图像,分析峰值标准化摄取值、肿瘤-本底比和乏氧体积。
- 基于探索队列,采用单变量和多变量Cox模型及一致性指数(ci)验证潜在预后参数对局部区域肿瘤控制(LRC)的影响,并用Log-rank检验比较风险组间终点。
主要发现
- 两个队列在肿瘤体积、乏氧体积、HPV状态和间发性死亡等基线参数上存在显著差异。
- 多个FMISO-PET参数验证成功,治疗第1周和第2周后预测性能最高,ci=0.77–0.81。
- FMISO-PET参数的截断值可在放化疗第2周后得到验证。
- 残余乏氧体积(定义为放化疗第2周乏氧体积与基线乏氧体积之比)的中位值应用于另一队列时,可将患者分为LRC显著不同的组。
关键数值与推荐
- 残余乏氧体积定义为放化疗第2周乏氧体积与基线乏氧体积的比值。
- FMISO-PET参数在治疗第1–2周后预测局部区域控制的ci为0.77–0.81。
- FMISO-PET参数的截断值可在放化疗第2周后验证。
临床怎么用
- 对于接受原发放化疗的头颈鳞癌患者,可考虑在治疗第2周左右行FMISO-PET评估残余乏氧。
- 治疗第2周残余乏氧体积比值可用于筛选局部区域复发高危患者,辅助后续治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypoxia is a well recognised parameter of tumour resistance to radiotherapy, a number of anticancer drugs and potentially immunotherapy. In a previously published exploration cohort of 25 head and neck squamous cell carcinoma (HNSCC) patients on [18F]fluoromisonidazole positron emission tomography (FMISO-PET) we identified residual tumour hypoxia during radiochemotherapy, not before start of treatment, as the driving mechanism of hypoxia-mediated therapy resistance. Several quantitative FMISO-PET parameters were identified as potential prognostic biomarkers. Here we present the results of the prospective validation cohort, and the overall results of the study. METHODS: FMISO-PET/CT images of further 25 HNSCC patients were acquired at four time-points before and during radiochemotherapy (RCHT). Peak standardised uptake value, tumour-to-background ratio, and hypoxic volume were analysed. The impact of the potential prognostic parameters on loco-regional tumour control (LRC) was validated by the concordance index (ci) using univariable and multivariable Cox models based on the exploration cohort. Log-rank tests were employed to compare the endpoint between risk groups. RESULTS: The two cohorts differed significantly in several baseline parameters, e.g., tumour volume, hypoxic volume, HPV status, and intercurrent death. Validation was successful for several FMISO-PET parameters and showed the highest performance (ci=0.77-0.81) after weeks 1 and 2 of treatment. Cut-off values for the FMISO-PET parameters could be validated after week 2 of RCHT. Median values for the residual hypoxic volume, defined as the ratio of the hypoxic volume in week 2 of RCHT and at baseline, stratified patients into groups of significantly different LRC when applied to the respective other cohort. CONCLUSION: Our study validates that residual tumour hypoxia during radiochemotherapy is a major driver of therapy resistance of HNSCC, and that hypoxia after the second week of treatment measured by FMISO-PET may serve as biomarker for selection of patients at high risk of loco-regional recurrence after state-of-the art radiochemotherapy.
引用
- Löck S, Perrin R, Seidlitz A, et al. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. Radiother Oncol. 2017. PMID: 28843726. doi:10.1016/j.radonc.2017.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。